SPRO
Spero Therapeutics Inc

2,722
Loading...
Loading...
News
all
press releases
Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Spero Therapeutics (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease
BAYRY begins human trials for OpCT-001, an experimental cell therapy for treating primary photoreceptor diseases.
Zacks·3mo ago
News Placeholder
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
Zacks·3mo ago
News Placeholder
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.
Zacks·3mo ago
News Placeholder
RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance
FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.
Zacks·3mo ago
News Placeholder
ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B
AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.
Zacks·3mo ago
News Placeholder
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why
The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.
Zacks·3mo ago
News Placeholder
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal
Zacks·4mo ago
News Placeholder
GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled
The early stop follows the trial meeting its primary endpoint of non-inferiority of Tebipenem HBr compared to an intravenous medicine in hospitalised adult patients with cUTI, including Pyelonephritis, where the infection spreads from the bladder to the kidneys.
Stocktwits·4mo ago
News Placeholder
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates
Zacks·4mo ago

Latest SPRO News

View

Advertisement. Remove ads.

Advertisement. Remove ads.